Disease progression in non-erosive reflux disease (NERD): Impact of initial esophageal acid exposure

Diseases of the Esophagus

Volumn 23, Issue 8, 2010, Pages 613-617

  Chen, C L ^a   Liu, T T ^a   Yi, C H ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

Author keywords

Gastroesophageal reflux; Long term follow up; NERD; Proton pump inhibitors

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; RABEPRAZOLE;

ACIDITY; ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DRUG USE; ESOPHAGUS MUCOSA; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HUMAN; MALE; NON EROSIVE REFLUX DISEASE; OUTCOME ASSESSMENT; PH MEASUREMENT; PRIORITY JOURNAL; REFLUX ESOPHAGITIS;

ADULT; ANTI-ULCER AGENTS; DISEASE PROGRESSION; ENDOSCOPY, GASTROINTESTINAL; EPISODE OF CARE; ESOPHAGEAL PH MONITORING; ESOPHAGITIS, PEPTIC; FEMALE; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TAIWAN; TIME;

EID: 78649501742     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2010.01071.x     Document Type: Article

References (32)

1. Moayyedi P, Talley N J. Gastro-oesophageal reflux disease. Lancet 2006; 367: 2086-100.
2. Lind T, Havelund T, Carlsson R et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 974-9.
3. Ronkainen J, Aro P, Storskrubb T et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol 2005; 40: 275-85.
4. Quigley E M. Gastro-oesophageal reflux disease-spectrum or continuum? QJM 1997; 90: 75-8.
5. Chen C L, Yi C H, Cook I J. Differences in oesophageal bolus transit between patients with and without erosive reflux disease. Dig Liver Dis 2008; 40: 348-54.
6. Martinez S D, Malagon I B, Garewal H S, Cui H, Fass R. Non-erosive reflux disease (NERD) - acid reflux and symptom patterns. Aliment Pharmacol Ther 2003; 17: 537-45.
7. Quigley E M, DiBaise J K. Non-erosive reflux disease: the real problem in gastro-oesophageal reflux disease. Dig Liver Dis 2001; 33: 523-7.
8. Richter J E, Bochenek W. Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group. Am J Gastroenterol 2000; 95: 3071-80.
9. Sontag S J, Hirschowitz B I, Holt S et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the US Multicenter Study. Gastroenterology 1992; 102: 109-18.
10. Armstrong D, Pare P, Pericak D, Pyzyk M. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. Am J Gastroenterol 2001; 96: 2849-57.
11. Johnson D A, Orr W C, Crawley J A et al. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial. Am J Gastroenterol 2005; 100: 1914-22.
12. Dean B B, Gano A D, Jr, Knight K, Ofman J J, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2: 656-64.
13. Lind T, Havelund T, Lundell L et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999; 13: 907-14.
14. Tew S, Jamieson G G, Pilowsky I, Myers J. The illness behavior of patients with gastroesophageal reflux disease with and without endoscopic esophagitis. Dis Esophagus 1997; 10: 9-15.
15. Yi C H, Chen C L, Lin H H, Chen M C. Esophageal acid exposure in healthy adults in Taiwan: experience with pH step-up method by dual-channel pH-metry. Kaohsiung J Med Sci 2005; 21: 299-303.
16. Lundell L R, Dent J, Bennett J R et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172-80.
17. Chen C L, Orr W C, Yang C C, Kuo T B. Cardiac autonomic regulation differentiates reflux disease with and without erosive esophagitis. Scand J Gastroenterol 2006; 41: 1001-6.
18. Schenk B E, Kuipers E J, Klinkenberg-Knol E C et al. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 1997; 92: 1997-2000.
19. Frazzoni M, De Micheli E, Savarino V. Different patterns of oesophageal acid exposure distinguish complicated reflux disease from either erosive reflux oesophagitis or non-erosive reflux disease. Aliment Pharmacol Ther 2003; 18: 1091-8.
20. Fass R. Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003; 98: S2-7.
21. Isolauri J, Luostarinen M, Isolauri E, Reinikainen P, Viljakka M, Keyrilainen O. Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. Am J Gastroenterol 1997; 92: 37-41.
22. Pace F, Bollani S, Molteni P, Bianchi Porro G. Natural history of gastro-oesophageal reflux disease without oesophagitis (NERD) - a reappraisal 10 years on. Dig Liver Dis 2004; 36: 111-5.
23. Labenz J, Nocon M, Lind T et al. Prospective follow-up data from the ProGERD study suggest that GERD is not a categorial disease. Am J Gastroenterol 2006; 101: 2457-62.
24. Kuster E, Ros E, Toledo-Pimentel V et al. Predictive factors of the long term outcome in gastro-oesophageal reflux disease: six year follow up of 107 patients. Gut 1994; 35: 8-14.
25. Pace F, Santalucia F, Bianchi Porro G. Natural history of gastro-oesophageal reflux disease without oesophagitis. Gut 1991; 32: 845-8.
26. Milkes D, Gerson L B, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal and intragastric pH in patients with gastroesophageal reflux disease (GERD). Am J Gastroenterol 2004; 99: 991-6.
27. Guelrud M, Herrera I, Essenfeld H, Castro J. Enhanced magnification endoscopy: a new technique to identify specialized intestinal metaplasia in Barrett's esophagus. Gastrointest Endosc 2001; 53: 559-65.
28. Quigley E M. New developments in the pathophysiology of gastro-oesophageal reflux disease (GERD): implications for patient management. Aliment Pharmacol Ther 2003; 17 (Suppl 2): 43-51.
29. Bate C M, Griffin S M, Keeling P W et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther 1996; 10: 547-55.
30. Miner P, Jr, Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol 2002; 97: 1332-9.
31. McDougall N I, Johnston B T, Collins J S, McFarland R J, Love A H. Three- to 4.5-year prospective study of prognostic indicators in gastro-oesophageal reflux disease. Scand J Gastroenterol 1998; 33: 1016-22.
32. Trimble K C, Douglas S, Pryde A, Heading R C. Clinical characteristics and natural history of symptomatic but not excess gastroesophageal reflux. Dig Dis Sci 1995; 40: 1098-104.